Genzyme, Impax Bury Hatchet Over Kidney Disease Drugs

Law360, New York (September 5, 2012, 7:39 PM EDT) -- Impax Laboratories Inc. on Tuesday settled patent infringement claims brought by Sanofi-Aventis SA subsidiary Genzyme Corp. over plans to make generic versions of two Genzyme kidney disease treatments, reaching a deal that will give Impax licensing rights in 2014.

Under the agreement, Impax may sell generic Renagel tablets in 400-milligram and 800-milligram dosages and generic Renvela liquid treatments in 2.4-gram and 0.8-gram dosages effective Sept. 16, 2014. Impax may sell generic Renvela 800-milligram tablets effective March 16, 2014.   

Tuesday’s settlement ends a protracted litigation battle...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.